Home / Conditions / Arthritis Oth Joint Dis
Arthritis Oth Joint Dis: when insurers say no, reviewers often say yes
In 40 published external-review decisions involving arthritis oth joint dis, independent physician reviewers overturned the insurer’s denial 80% of the time.
Published decisions
40
2001–2026
Overturned
80%
32 denials reversed
Most-fought treatments for arthritis oth joint dis
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Misc Drugs | 9 | 100% |
| Viscosupp Injection | 7 | 100% |
| Injection Admin Drugs | 3 | 66.7% |
| Biologics | 3 | 100% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 35 | 82.9% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 5 | 60% |
Typical time to a decision
6 days
Most land between 2 and 10 days
Handled as urgent
52.5%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Actemra. The American College of Rheumatology (ACR) guidelines for the treatment of rheumatoid arthritis specifically recommend that when patients have not responded adequately to one class of biologic therapy, such as tumor necrosis factor (TNF) inhibitors, switching to a different mechanism of action is conditionally recommended over continuing within the same class. In this case, the patient presents with seronegative rheumatoid arthritis and has failed multiple prior therapies, including two TNF inhibitors as well as conventional disease-modifying anti-rheumatic drugs. The ACR guidelines support the use of Actemra (tocilizumab) in this patient, which works through interleukin 6 receptor inhibition.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for suprascapular and axillary nerve radiofrequency ablation. A systematic review indicates that radiofrequency-based interventions targeting shoulder innervation can reduce chronic shoulder pain and improve function. Randomized trial data further show that applying radiofrequency energy to the suprascapular nerve distribution can provide clinically meaningful analgesic benefits compared with injection-based approaches in chronic shoulder pain populations. Prospective evidence also shows meaningful improvements in pain and function in appropriately selected patients with low rates of serious complications over follow-up.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Journavx. Suzetrigine (Journavx) is U.S. Food and Drug Administration (FDA)-approved for moderate-to-severe acute pain in adults, and the official prescribing information states that its use for acute pain has not been studied beyond 14 days. Therefore, for the indication being requested here, ongoing treatment of chronic ankle pain, chronic low back pain, and persistent shoulder/neck pain, continued use is not supported by the same level of evidence that underpins its FDA-approved, time-limited acute-pain indication. Evidence for chronic/peripheral neuropathic pain remains uncertain.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for implantation of the MISHA Knee System.Although some studies report improvement in pain and function with the MISHA Knee System and mid-term survivorship without conversion to arthroplasty, the current evidence base remains limited by nonrandomized study designs and lack of large comparative trials demonstrating superiority over established treatment pathways.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for arthritis oth joint dis was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.